Geron Corp GERN shares are trading lower in Wednesday’s after-hours session after the company announced a proposed public offering.
What To Know: Geron said it intends to sell $175 million of its common stock in an underwritten public offering. The company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of its common stock.
In Wednesday’s regular trading session, Geron shares soared above $4, before pulling back and closing up 32.9% at $3.19 after the company announced positive top-line results from a rare blood cancer trial.
Related Link: Geron Stock Surges After Encouraging Data From Rare Blood Cancer Trial
Geron is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies.
See Also: Why Vyant Bio Shares Are Soaring After Hours
GERN Price Action: Geron shares are down 11.3% in after-hours at $2.83 at the time of publication, according to Benzinga Pro.
Photo: fernando zhiminaicela from Pixabay.
Image and article originally from www.benzinga.com. Read the original article here.